Development and Delivery of an Integrated Digital Health Care Approach for Children With Juvenile Idiopathic Arthritis
Not Applicable
Not yet recruiting
- Conditions
- Juvenile Idiopathic ArthritisInflammatory and Immune System - Autoimmune diseasesMusculoskeletal - Other muscular and skeletal disorders
- Registration Number
- ACTRN12616000665437
- Lead Sponsor
- The University of Newcastle
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
1) Diagnosed with JIA according to ILAR (International League of Associations for Rheumatology) criteria.
2) No previous use of Apple-Watch
3) Resident in Australia
Exclusion Criteria
1) Concomitant musculoskeletal disease, central or peripheral nerve disease
2) Heart failure
3) Severe visual impairments
4) If DMARD and/or Biological therapy are used, not having started these drug therapies within 6 months of enrolling in the trial.
5) Where assistive drugs therapy administration is required daily by medical staff
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in lower limb pain as recorded by the iVAS app developed by the Dr Coda and his research and also by comparing it with the standard VAS (visual analogue scale). According to Dhanani et al. (2002), 8mm are required to achieve clinical significance difference between data collection sessions, in paediatric rheumatology children.[ baseline <br>3rd months <br>6th months <br>];Change in 'Quality of life' using the ‘disease specific’ (paediatric rheumatology) - PedsQL questionnaire divided according to the age range (gathered directly by the child and independently also by their parents / carer). According to Varni et al (2002), 5 points are required to achieve clinical significance difference between data collection sessions[ baseline <br>3rd month <br>6th month]
- Secondary Outcome Measures
Name Time Method